Episode 9: Antisense Oligonucleotides
Antisense oligonucleotides (ASOs) are being developed as treatments for rare genetic disorders such as SCN2A. What are they and how do they work? To help gain a better understanding of ASOs and their role we talk to Dr Stanley Crooke, founder of Ionis.
Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.
Dr. Stanley Crooke is the founder, chairman and chief executive officer of Ionis Pharmaceuticals. Under his leadership, Ionis pioneered development of the revolutionary antisense technology platform and created one of the largest, most advanced pipelines in the biotechnology industry. Today, Ionis has more than 40 medicines in development.
Prior to founding Ionis, Dr. Crooke was head of R&D at SmithKline. Earlier at Bristol-Myers, he established the first broad anticancer program, bringing nine drugs to the market in five years.
Ms Kris Pierce RN MHSc MWellness, is a rare disease advocate and mother to Will who has SCN2A. Kris has held a range of board, project management, advocate and consumer representative roles and has been instrumental in working with local, state and federal governments to secure funding for multi-million dollar projects. Kris is highly skilled in building teams to work together collaboratively and is a co-founder of Genetic Epilepsy Team Australia (GETA) and SCN2A Australia, and a RARE Global Advocacy Leadership Council member.